BRL
2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL)
Find entries where: BRL
is present as a standalone ligand in 13 entries
Chemical Component Summary | |
---|---|
Name | 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) |
Synonyms | BRL49653; ROSIGLITAZONE |
Identifiers | (5S)-5-[[4-[2-(methyl-pyridin-2-yl-amino)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
Formula | C18 H19 N3 O3 S |
Molecular Weight | 357.427 |
Type | NON-POLYMER |
Isomeric SMILES | CN(CCOc1ccc(cc1)C[C@H]2C(=O)NC(=O)S2)c3ccccn3 |
InChI | InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)/t15-/m0/s1 |
InChIKey | YASAKCUCGLMORW-HNNXBMFYSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 44 |
Chiral Atom Count | 1 |
Bond Count | 46 |
Aromatic Bond Count | 12 |
Drug Info: DrugBank
DrugBank ID | DB00412 |
---|---|
Name | Rosiglitazone |
Groups |
|
Description | Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway. |
Synonyms |
|
Brand Names |
|
Indication | Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
Categories |
|
ATC-Code |
|
CAS number | 122320-73-4 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Peroxisome proliferator-activated receptor gamma | MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDL... | unknown | agonist |
Long-chain-fatty-acid--CoA ligase 4 | MKLKLNVLTIILLPVHLLITIYSALIFIPWYFLTNAKKKNAMAKRIKAKP... | unknown | inhibitor |
Peroxisome proliferator-activated receptor alpha | MVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFG... | unknown | |
Peroxisome proliferator-activated receptor delta | MEQPQEEAPEVREEEEKEEVAEAEGAPELNGGPQHALPSSSYTDLSRSSS... | unknown | |
Retinoic acid receptor RXR-alpha | MDTKHFLPLDFSTQVNSSLTSPTGRGSMAAPSLHPSLGPGIGSPGQLHSP... | unknown | |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL121106 |
PubChem | 445655 |
ChEMBL | CHEMBL121106 |
ChEBI | CHEBI:50125 |
CCDC/CSD | KIWVUI |